Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis.
Clin Mol Hepatol
; 27(4): 535-552, 2021 10.
Article
em En
| MEDLINE
| ID: mdl-34130370
ABSTRACT
Although patients with cirrhosis are known to be in a state of "rebalance" in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Trombose
/
Trombose Venosa
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article